Publications

Found 1 results
Filters: Author is C.S. Frade  [Clear All Filters]
2012
D. A. P. C. Zuccari, Castro, R., Gavioli, A. F., Mancini, U. M., Frade, C. S., and Leonel, C., Immunohistochemical and molecular analysis of caveolin-1 expression in canine mammary tumors, vol. 11, pp. 153-165, 2012.
Allred CD, Harvey JM, Berardo M and Clark GM (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11: 155-168. PMid:19542014    PMCid:2728297 Amorim I, Lopes CC, Faustino AM and Pereira PD (2010). Immunohistochemical expression of caveolin-1 in normal and neoplastic canine mammary tissue. J. Comp. Pathol. 143: 39-44. PMid:19578358    PMCid:2769203 Bat’ová Z, Bittnerova M, Krenek P and Kyselovic J (2003). Caveolar functions and caveolin structural proteins. Cesk. Fysiol. 52: 166-171. PMid:15322703 Bouras T, Lisanti MP and Pestell RG (2004). Caveolin-1 in breast cancer. Cancer Biol. Ther. 3: 931-941. PMid:18258830 Chen ST, Lin SY, Yeh KT, Kuo SJ, et al. (2004). Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int. J. Mol. Med. 14: 577-582. PMid:21671123 Cordeiro JA (1987). Analysis of Dependency. Relatório Técnico N° 48/87. Instituto de Matemática e Estatística, Unicamp, Campinas. PMid:11679670 Elsheikh SE, Green AR, Rakha EA, Samaka RM, et al. (2008). Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer 99: 327-334. PMid:19075105 Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, et al. (2009). The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Vet. Comp. Oncol. 7: 230-235. PMid:18451334    PMCid:2574857 Glait C, Tencer L, Ravid D, Sarfstein R, et al. (2006). Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp. Cell Res. 312: 3899-3908. PMid:12091877 Lee H, Park DS, Razani B, Russell RG, et al. (2002). Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol. 161: 1357-1369. PMid:7624392 Liedtke C, Kersting C, Burger H, Kiesel L, et al. (2007). Caveolin-1 expression in benign and malignant lesions of the breast. World J. Surg. Oncol. 5: 110. PMid:19888324    PMCid:2765616 Mercier I, Casimiro MC, Wang C, Rosenberg AL, et al. (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol. Ther. 7: 1212-1225. Pereira PD, Lopes CC, Matos AJ, Cortez PP, et al. (2010). Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems. J. Comp. Pathol. 143: 87-93. Savage K, Lambros MB, Robertson D, Jones RL, et al. (2007). Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 13: 90-101. Shajahan AN, Wang A, Decker M, Minshall RD, et al. (2007). Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J. Biol. Chem. 282: 5934-5943. Sloan EK, Stanley KL and Anderson RL (2004). Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, et al. (2009). Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet. Comp. Oncol. 7: 162-172. Sotgia F, Rui H, Bonuccelli G, Mercier I, et al. (2006). Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 66: 10647-10651. Vandesompele J, De Preter K, Pattyn F, Poppe B, et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3: RESEARCH0034. Wang Y, Yu J and Zhan Q (2008). BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness. Biochem. Biophys. Res. Commun. 370: 201-206. WHO (2007). World Health Organization-Air Force Institute of Pathology Classification System for Canine Mammary Tumors. Available at [http://www.who.int/en/]. Accessed July 5, 2009. Williams TM and Lisanti MP (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol. 288: C494-C506. Williams TM, Cheung MW, Park DS, Razani B, et al. (2003). Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol. Biol. Cell 14: 1027-1042. Williams TM, Medina F, Badano I, Hazan RB, et al. (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279: 51630-51646. Williams TM, Sotgia F, Lee H, Hassan G, et al. (2006). Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am. J. Pathol. 169: 1784-1801. Zhu H, Weisleder N, Wu P, Cai C, et al. (2008). Caveolae/caveolin-1 are important modulators of store-operated calcium entry in Hs578/T breast cancer cells. J. Pharmacol. Sci. 106: 287-294.